Suppr超能文献

印度的慢性肾脏病:挑战与解决方案。

Chronic kidney disease in India: challenges and solutions.

作者信息

Agarwal S K, Srivastava R K

机构信息

Department of Nephrology, All India Institute of Medical Sciences, New Delhi, India.

出版信息

Nephron Clin Pract. 2009;111(3):c197-203; discussion c203. doi: 10.1159/000199460. Epub 2009 Feb 5.

Abstract

Chronic diseases have become a major cause of global morbidity and mortality even in developing countries. The burden of chronic kidney disease (CKD) in India cannot be assessed accurately. The approximate prevalence of CKD is 800 per million population (pmp), and the incidence of end-stage renal disease (ESRD) is 150-200 pmp. The most common cause of CKD in population-based studies is diabetic nephropathy. India currently has 820+ nephrologists, 710+ hemodialysis units with 2,500+ dialysis stations and 4,800+ patients on CAPD. There are 172+ transplant centers, two-thirds of which are in South India and mostly privately run. Nearly 3,500 transplants are done annually, the total number of cadaver donors being approximately 700 till now. Thus, taken together, nearly 18,000-20,000 patients (10% of new ESRD cases) in India get renal replacement therapy. The cost of single hemodialysis varies between USD 15 and 40 with an additional cost of erythropoietin being USD 150-200/month. The cost of CAPD using a 'Y' set with 3 exchanges/week is USD 400/month. The cost of the transplant procedure in a state-run hospital is USD 800-1,000, and the cost of immunosuppression using tacrolimus, steroid and mycophenolate is USD 350-400/month. Until recently, the government did not recognize CKD/ESRD as a significant problem in India. However, some illustrious activities in relation to CKD brought attention of the media and policymakers to this very common but till now deprived group of diseases. On the one side the government has initiated a process by which it is planning to establish stand-alone hemodialysis units in the country to increase the facilities at an affordable cost, and on the transplant side it had launched a National Organ Transplant Program to facilitate transplantation on a national scale. Hemodialysis program is halfway to being implemented. Thus, in India there is still a long way to go with respect to CKD. Until then, in a country like India, screening of high-risk individuals for CKD and the risk factors is the best bet.

摘要

即使在发展中国家,慢性病也已成为全球发病和死亡的主要原因。印度慢性肾脏病(CKD)的负担难以准确评估。CKD的大致患病率为每百万人口800例(pmp),终末期肾病(ESRD)的发病率为150 - 200 pmp。在基于人群的研究中,CKD最常见的病因是糖尿病肾病。印度目前有820多名肾病学家、710多个血液透析单位,配备2500多个透析站,4800多名患者接受持续性非卧床腹膜透析(CAPD)治疗。有172多个移植中心,其中三分之二在印度南部,且大多为私立。每年进行近3500例移植手术,到目前为止尸体供体总数约为700例。因此,综合来看,印度有近18000 - 20000名患者(占新ESRD病例的10%)接受肾脏替代治疗。单次血液透析的费用在15美元至40美元之间,促红细胞生成素的额外费用为每月150 - 200美元。每周进行3次交换使用“Y”型装置的CAPD费用为每月400美元。在国营医院进行移植手术的费用为800 - 1000美元,使用他克莫司、类固醇和霉酚酸进行免疫抑制的费用为每月350 - 400美元。直到最近,印度政府才认识到CKD/ESRD是一个重大问题。然而,一些与CKD相关的杰出活动引起了媒体和政策制定者对这一非常常见但至今仍被忽视的疾病群体的关注。一方面,政府已启动一个进程,计划在国内建立独立的血液透析单位,以以可承受的成本增加设施,另一方面,政府已启动一项全国器官移植计划,以促进全国范围内的移植。血液透析计划已实施了一半。因此,在印度,就CKD而言仍有很长的路要走。在此之前,在像印度这样的国家,对高危个体进行CKD及其危险因素的筛查是最佳选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验